Vaxcyte to Present Results from VAX-24 Infant Study
SAN CARLOS, Calif. — Vaxcyte, Inc. (NASDAQ: PCVX), a leader in vaccine innovation, has announced an upcoming webcast and conference call to discuss the topline results of its VAX-24 infant Phase 2 study. The event is scheduled for 8:00 a.m. Eastern Time, where insights will be shared regarding the efficacy and safety profiles of their groundbreaking 24-valent pneumococcal conjugate vaccine (PCV) candidate.
Understanding VAX-24 and Its Impact
The VAX-24 study focuses on evaluating the safety and tolerability of this innovative vaccine compared to the existing Prevnar 20 in healthy infants. This product aims to combat invasive pneumococcal disease (IPD), which poses significant health risks to young children. By addressing a wider serotype range than current vaccines, VAX-24 is set to enhance pediatric health outcomes.
Conference Call Participation Details
Interested participants can join the conference call by dialing 800-445-7795 for domestic lines and 785-424-1699 for international calls. Referencing the conference ID PCVX0331 will streamline the process. In addition, a live webcast will be accessible on Vaxcyte's investor relations page, with an archived version available for 30 days post-event.
Innovative Solutions in Vaccine Development
Vaxcyte is redefining vaccine development through its commitment to creating high-fidelity vaccines. The company utilizes a modern synthesis technique, the XpressCF™ cell-free protein synthesis platform, which allows for more efficient vaccine production compared to traditional cell-based methods. This cutting-edge technology is pivotal in the creation of complex proteins aimed at robust immunological responses.
The Future of Pneumococcal Vaccines
VAX-31, Vaxcyte’s 31-valent PCV candidate, is progressing towards a Phase 3 clinical program for adults and infants. The anticipated results from both VAX-24 and VAX-31 could significantly influence the preventive strategies we adopt against pneumonia-related illnesses. With a focus on high-risk serotypes associated with severe health consequences, these vaccines aim to make a meaningful impact.
Addressing Market Needs
The ongoing challenges posed by antibiotic resistance and meningitis underscore the need for advanced vaccination solutions. Vaxcyte’s approach goes beyond current standards, as both VAX-24 and VAX-31 aim to cover circulating strains and those previously contained by vaccination efforts. This strategic direction is crucial in the context of rising IPD incidence rates.
Focus on Patient and Community Health
Vaxcyte is driven by a mission to eradicate or effectively manage invasive bacterial infections, with a strong understanding of their profound health implications. Its comprehensive pipeline also includes promising vaccine candidates like VAX-A1, VAX-PG, and VAX-GI, targeting various infectious diseases, thereby showcasing its commitment to enhancing community health outcomes.
Corporate Contact Information
For more details on Vaxcyte’s innovations and upcoming events, please contact:
Patrick Ryan, Executive Director, Corporate Affairs
Vaxcyte, Inc.
415-606-5135
media@vaxcyte.com
Jennifer Zibuda, Senior Director, Investor Relations
Vaxcyte, Inc.
860-729-8902
investors@vaxcyte.com
Frequently Asked Questions
What is VAX-24?
VAX-24 is Vaxcyte's 24-valent pneumococcal conjugate vaccine designed to prevent invasive pneumococcal disease in infants.
When will the results of the VAX-24 study be presented?
The results will be discussed in a webcast and conference call scheduled for 8:00 a.m. Eastern Time.
How does VAX-24 compare to existing vaccines?
VAX-24 covers more serotypes than any current infant PCV available on the market, potentially offering broader protection.
What innovative technologies does Vaxcyte use?
Vaxcyte employs the XpressCF™ cell-free protein synthesis platform to create vaccines more efficiently and effectively.
What other products are in Vaxcyte's pipeline?
In addition to VAX-24, Vaxcyte is developing VAX-31, VAX-A1, VAX-PG, and VAX-GI to address various bacterial infections.
